Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach
Kapil Gadkar(Sea Turtle Conservancy), Saroja Ramanujan(Unknown), John D. Davis(Providence College), James Lu(Genesys (United States)), Srikumar Sahasranaman(University of Nottingham), Norman A. Mazer(Roche (Switzerland))
Cited by 19
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
|Journal of the American Academy of Dermatology|2020|396
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373